Total trials
114
Active
25
Phase 3
1
Total enrollment
399,346
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Rituximab | — | — | — | — | — | 1 | |
| Intravenous immunoglobulin | — | — | — | — | 2 | ||
| Whole-genome sequencing | — | — | — | — | — | 1 | |
| Inclisiran | — | — | — | — | — | 1 | |
| Colchicine | — | — | — | — | — | 1 |
Next readouts
- 2025-09-30
- 2025-10-01
- 2027-04-30
Top conditions
- Type 1 Diabetes17
- Type 1 Diabetes Mellitus6
- Diabetes Mellitus6
- Diabetes Mellitus, Type 14
- Glucose Metabolism Disorders4
- Endocrine System Diseases4
- Stroke4
- Type 2 Diabetes3
Frequently asked questions about University of Cambridge
- How many clinical trials does University of Cambridge have on ClinicalTrials.gov?
- University of Cambridge is listed as the lead sponsor on 114 clinical trials in ClinicalTrials.gov, 25 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Cambridge's trials are in Phase 3?
- 1 of University of Cambridge's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does University of Cambridge focus on?
- University of Cambridge's most-studied conditions on ClinicalTrials.gov are Type 1 Diabetes, Type 1 Diabetes Mellitus, Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders.
- When are University of Cambridge's next clinical trial readouts?
- University of Cambridge has 3 upcoming primary-completion readouts tracked here; the soonest is “NeuralNET Cerebral Palsy Pilot Study”, expected around 2025-09-30.